Accueil>>EGFRvIII Peptide (trifluoroacetate salt)

EGFRvIII Peptide (trifluoroacetate salt)

Catalog No.GC91027

Un fragment de peptide EGFRvIII

Products are for research use only. Not for human use. We do not sell to patients.

EGFRvIII Peptide (trifluoroacetate salt) Chemical Structure

Taille Prix Stock Qté
1 mg
36,00 $US
En stock
5 mg
163,00 $US
En stock
10 mg
288,00 $US
En stock
25 mg
632,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

EGFRvIII peptide is a synthetic peptide that corresponds to the fusion junction of EGFRvIII, a tumor-specific, constitutively active variant of EGFR that lacks amino acids 6-273 of wild-type EGFR.1,2 It binds to MHC class I subtype HLA-A*0201-positive T2 cells when used at a concentration of 25 µg/ml.1 EGFRvIII peptide induces antigen presentation in dendritic cells derived from isolated human peripheral blood mononuclear cells (PBMCs), which stimulates activation of, and IFN-γ production by, CD8+ cytotoxic T lymphocytes. Immunization with EGFRvIII peptide (15 µg/animal), in combination with the toll-like receptor 5 (TLR5) agonist flagellin B, increases the number of CD8+ T cells and decreases the number of regulatory T cells (Tregs) in the brain, reduces tumor volume, and increases survival rate in an orthotopic GL261 glioblastoma mouse xenograft model.2

Avis

Review for EGFRvIII Peptide (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EGFRvIII Peptide (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.